Campylobacter jejuni is the leading bacterial cause of human enteritis in the United States and other industrialized countries. This pathogenic organism causes watery diarrhea and/ or hemorrhagic colitis in humans and is also associated with Guillain-BarrÃ© syndrome, an acute flaccid paralysis that may lead to respiratory muscle compromise and death. Poultry are the major reservoir of Campylobacter and thus the main source for human campylobacteriosis. At the same time that prevalence of infection is increasing, Campylobacter has become increasingly resistant to antibiotics, including fluoroquinolones and macrolides, the major drugs of choice for treating human campylobacteriosis. Despite the growing need for new antibiotics due to increasing drug resistance in Campylobacter and other bacteria, many pharmaceutical companies have been placing less emphasis on antibiotic discovery. Therefore, alternative intervention strategies, such as vaccination, are needed to prevent and control Campylobacter infections. To dates, vaccines against Campylobacter infection are still not available, primarily due to the antigenic complexity of this organism and a lack of understanding of the mechanisms of pathogenesis. Information concerning protective antigens as vaccine candidates in C. jejuni is limited and vaccinations against C. jejuni using animal models including chickens have had only partial success.
Development and Evaluation of CmeC Subunit Vaccine against Campylobacter jejuni: Ximin Zeng, Fuzhou Xu and Jun Lin
Last date updated on February, 2021